Hector Tejeda-Mora

Dr. Hector Tejeda-Mora

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
HSHelena Shomar
Helena Shomar
SGSophie Gontier
Sophie Gontier
NBNiels J. F. van Den Broek
Niels J. F. van Den Broek
HTHector Tejeda-Mora
Hector Tejeda-Mora
MNMarek Noga
Marek Noga
GBGregory Bokinsky
Gregory Bokinsky

26 April 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HTHector Tejeda-Mora
Hector Tejeda-Mora
JVJ. G. H. P. Verhoeven
J. G. H. P. Verhoeven
WVW. Verschoor
W. Verschoor
KBK. Boer
K. Boer
DHD. A. Hesselink
D. A. Hesselink
MHMartin J. Hoogduijn
Martin J. Hoogduijn
The diagnosis of kidney allograft rejection is based on late histological and clinical markers. Early, specific and minimally-invasive biomarkers may improve rejection diagnosis. Endothelial cells (EC) are one of the earliest targets in kidney transplant rejection. We investigated whether circulating EC (cEC) could serve as an earlier and less invasive biomarker for allograft rejection. Blood was collected from a cohort of 51 kidney transplant recipients before and at multiple timepoints after transplantation, including during a for cause biopsy. The number and phenotype of EC was assessed by flow-cytometric analysis. Unbiased selection of EC was done using principal component (PCA) analysis. Paired analysis revealed a transient cEC increase of 2.1-fold on the third day post-transplant, recovering to preoperative levels at seventh day post-transplant and onwards. Analysis of HLA subtype demonstrated that cEC mainly originate from the recipient. cEC levels were not associated with allograft rejection, allograft function or other allograft pathologies. However, cEC in patients with allograft rejection and increased levels of cEC showed elevated levels of KIM-1 (kidney injury marker-1). These findings indicate that cEC numbers and phenotype are affected after kidney transplantation but may not improve rejection diagnosis.

Verified
Journal Article
Open access
PDF file
HTHector Tejeda-Mora
Hector Tejeda-Mora
LLLeticia G. Leon
Leticia G. Leon
Jeroen A. A. DemmersJeroen A. A. Demmers
Jeroen A. A. Demmers
Carla C. BaanCarla C. Baan
Carla C. Baan
MRMarlies E. J. Reinders
Marlies E. J. Reinders
MHMartin J. Hoogduijn
Martin J. Hoogduijn
Extracellular vesicles (EV) derived from mesenchymal stromal cells (MSC) are a potential therapy for immunological and degenerative diseases. However, large-scale production of EV free from contamination by soluble proteins is a major challenge. The generation of particles from isolated membranes of MSC, membrane particles (MP), may be an alternative to EV. In the present study we generated MP from the membranes of lysed MSC after removal of the nuclei. The yield of MP per MSC was 1 × 105 times higher than EV derived from the same number of MSC. To compare the proteome of MP and EV, proteomic analysis of MP and EV was performed. MP contained over 20 times more proteins than EV. The proteins present in MP evidenced a multi-organelle origin of MP. The projected function of the proteins in EV and MP was very different. Whilst proteins in EV mainly play a role in extracellular matrix organization, proteins in MP were interconnected in diverse molecular pathways, including protein synthesis and degradation pathways and demonstrated enzymatic activity. Treatment of MSC with IFNγ led to a profound effect on the protein make up of EV and MP, demonstrating the possibility to modify the phenotype of EV and MP through modification of parent MSC. These results demonstrate that MP are an attractive alternative to EV for the development of potential therapies. Functional studies will have to demonstrate therapeutic efficacy of MP in preclinical disease models.

6 September 2022 in Journal of Controlled Release
Verified
Journal Article
Open access
JVJ. Vos
J. Vos
HTHector Tejeda-Mora
Hector Tejeda-Mora
AMA. Merino
A. Merino
LWLiang Wu
Liang Wu
WWW.W. Woud
W.W. Woud
MHMartin J. Hoogduijn
Martin J. Hoogduijn
Vesicle-based medicines hold great promise for therapy development but essential knowledge on the bio-distribution and longevity of vesicles after administration is lacking. We generated vesicles from the membranes of human mesenchymal stromal cells (MSC) and we demonstrated earlier that these so-called membrane particles (MP) mediate immunomodulatory and regenerative responses in target cells. In the present study we examined the bio-distribution and longevity of MP after intravenous administration in mice. While most vesicle tracking methods are based on imaging techniques, which require labeling of vesicles and can only detect dense accumulations of vesicles, we used proteomics analysis to detect the presence of MP-derived proteins in multiple organs and tissues. MP proteins were mainly present in plasma and leukocytes at 1 h after injection, indicating that MP - in contrast to whole MSC - do not accumulate in the lungs upon first passage but remain in circulation. After 24 h, MP proteins were still present in plasma but were most abundant in the liver. RNA sequencing of livers demonstrated that MP impact liver function and in particular induce metabolic pathways. These data provide a clear view of the bio-distribution and longevity of MP, which is likely extrapolatable to other types of vesicles, and demonstrate that MP circulate for up to 24 h and may be a tool for targeting the liver.

4 March 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
DHDaphne M. Hullegie-Peelen
Daphne M. Hullegie-Peelen
HTHector Tejeda-Mora
Hector Tejeda-Mora
MDMarjolein Dieterich
Marjolein Dieterich
SHSebastiaan Heidt
Sebastiaan Heidt
EBeric bindels
eric bindels
Carla C. BaanCarla C. Baan
Carla C. Baan
The extent to which tissue-resident memory T (TRM) cells in transplanted organs possess alloreactivity is uncertain. This study investigates the alloreactive potential of TRM cells in kidney explants from four patients who experienced severe acute rejection leading to graft loss. Alloreactive T cell receptor (TCRs) clones were identified in pre-transplant blood samples through mixed lymphocyte reactions, followed by single-cell RNA and TCR sequencing of the proliferated recipient T cells. Subsequently, these TCR clones were traced in the TRM cells of kidney explants, which were also subjected to single-cell RNA and TCR sequencing. The proportion of recipient-derived TRM cells expressing an alloreactive TCR in the four kidney explants varied from 0% to 9%. Notably, these alloreactive TCRs were predominantly found among CD4+ and CD8+ TRM cells with an effector phenotype. Intriguingly, these clones were present not only in recipient-derived TRM cells but also in donor-derived TRM cells, constituting up to 4% of the donor population, suggesting the presence of self-reactive TRM cells. Overall, our study demonstrates that T cells with alloreactive potential present in the peripheral blood prior to transplantation can infiltrate the kidney transplant and adopt a TRM phenotype.

1 January 2024 in Stem Cells and Development
Verified
Journal Article
Closed access
HTHector Tejeda-Mora
Hector Tejeda-Mora
YHYvette Den Hartog
Yvette Den Hartog
ISIvo J. Schurink
Ivo J. Schurink
Monique M. A. VerstegenMonique M. A. Verstegen
Monique M. A. Verstegen
JJJeroen de Jonge
Jeroen de Jonge
JWJorke Willemse
Jorke Willemse
Allogeneic transplant organs are potentially highly immunogeneic. The endothelial cells (EC) located within the vascular system serve as the primary interface between the recipient’s immune system and the donor organ, playing a key role in the allo-immune response. In this study, we investigated the potential use of recipient-derived ECs in a vein recellularization model. Here, human iliac veins underwent complete decellularization using a triton X-100 protocol. We demonstrated the feasibility of re-endothelializing acellular blood vessels using either HUVEC or human venous-derived ECs, with this re-endothelization being sustainable for up to 28 days in vitro. The re-endothelialized veins exhibited the restoration of vascular barrier function, along with the restoration of innate immune regulatory capabilities, evident through the facilitation of monocytic cell transmigration and their polarization towards a macrophage phenotype following trans-endothelial extravasation. Finally, we explored whether recellularization with EC of a different donor could prevent antibody-mediated rejection. We demonstrated that in chimeric vessels, allogeneic EC became a target of the humoral anti-donor response after activation of the classical immune complement pathway whereas autologous EC were spared, emphasizing their potential utility prior to transplantation. In conclusion, our study demonstrates that replacement of EC in transplants could reduce the immunological challenges associated with allogeneic grafts.